News

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward

Christmas came early for Cerevel Therapeutics shareholders courtesy of AbbVie Inc. (NYSE:ABBV). 

Last week, AbbVie announced a plan to acquire the Massachusetts-based biotechnology company in an

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. (NYSE: HUM) is reportedly in talks to merge with The Cigna Group (NYSE: CI) in a stock-and-cash deal

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic (NYSE: MDT) has finally reached its bottom, and the reversal is

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many